Stocktoria
Nuo Therapeutics, Inc. AURX
Nuo Therapeutics, Inc. (AURX) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $3.3M at a -75.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Manufacturing · percentile among 2036 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| AURX | Nuo Therapeutics, Inc. | 3/9 | — | — | — |
| OSRH | OSR Health, Inc. | — | 1.04 | — | — |
| USAQ | QHSLab, Inc. | 4/9 | -1.02 | — | — |
| TNON | Tenon Medical, Inc. | 5/9 | — | — | — |
| INBS | INTELLIGENT BIO SOLUTIONS INC. | 2/9 | — | — | — |
| FEMY | FEMASYS INC | 2/9 | — | — | — |
| LUCD | Lucid Diagnostics Inc. | 3/9 | — | — | — |
About Nuo Therapeutics, Inc.
Nuo Therapeutics, Inc. operates as a regenerative therapies company that develops, commercializes, and markets cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing in the United States. The company offers the Aurix System, which separates autologous blood to produce a platelet-based therapy for the chronic wound care market. Its customers include hospital outpatient wound care clinics and other private practice physicians treating chronic wounds. The company was formerly known as Cytomedix, Inc. and changed its name to Nuo Therapeutics, Inc. in November 2014. Nuo Therapeutics, Inc. was incorporated in 1998 and is based in Houston, Texas.
FAQ
Is AURX financially healthy?
Nuo Therapeutics, Inc.'s Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does AURX pay a dividend?
No, Nuo Therapeutics, Inc. does not currently pay a dividend.
How profitable is AURX?
In FY2025, Nuo Therapeutics, Inc. had a net margin of -75.8%.
Is AURX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Nuo Therapeutics, Inc.: a Piotroski F-score of 3/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.